Skip to main content
Fig. 9 | BMC Cancer

Fig. 9

From: Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

Fig. 9

Assessment of epigenetic drug-mediated sensitization of cytarabine resistant cells. Proliferation of Z138-CytR cells exposed to different concentrations of six epigenetic drugs for 6 hours, prior to addition of 50 μM cytarabine. Several epigenetic drugs showed a tendency to re-sensitize Z138-CytR to cytarabine, at the lowest concentration (0.1 μM). Each data point represents mean relative proliferation ± SEM of three independent experiments. * = p < 0.05 and ** = p < 0.01, using students unpaired t-test. The data, collected 30 h after treatment, are normalized to the 0-h time-point and the R10 medium control (+/− cytarabine)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us